{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Targeted+TKI+therapy", "query": { "intervention": "Targeted TKI therapy" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 24, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Targeted+TKI+therapy&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-08T22:32:04.486Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05370469", "title": "Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Lung Cancer", "EGFR Gene Mutation", "EGFR", "ALK Gene Mutation", "RET Gene Mutation", "MET Gene Mutation", "KRAS Mutation-Related Tumors", "BRAF", "ROS1 Gene Mutation" ], "interventions": [ { "name": "Sensus Smartwatch Application", "type": "OTHER" }, { "name": "RX Cap", "type": "DEVICE" }, { "name": "Fitbit Sense", "type": "DEVICE" }, { "name": "Surveys", "type": "OTHER" } ], "intervention_types": [ "OTHER", "DEVICE" ], "sponsor": "University of Virginia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2022-08-25", "completion_date": "2026-05", "has_results": false, "last_update_posted_date": "2025-11-25", "last_synced_at": "2026-09-08T22:32:04.486Z", "location_count": 1, "location_summary": "Charlottesville, Virginia", "locations": [ { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05370469" }, { "nct_id": "NCT04486833", "title": "Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Carcinoma, Non-Small Cell Lung" ], "interventions": [ { "name": "quaratusugene ozeplasmid", "type": "BIOLOGICAL" }, { "name": "osimertinib", "type": "DRUG" }, { "name": "Platinum-Based Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Genprex, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 158, "start_date": "2021-09-03", "completion_date": "2029-03", "has_results": false, "last_update_posted_date": "2026-01-21", "last_synced_at": "2026-09-08T22:32:04.486Z", "location_count": 10, "location_summary": "Los Angeles, California • Lone Tree, Colorado • Urbana, Illinois + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Lone Tree", "state": "Colorado" }, { "city": "Urbana", "state": "Illinois" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Rockville", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04486833" }, { "nct_id": "NCT05868226", "title": "PRE-ISPY Phase I/II Oncology Platform Program", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HER2-positive Breast Cancer", "Metastatic Cancer", "Metastatic Breast Cancer", "Metastatic", "HER2-positive Metastatic Breast Cancer", "HER2 Mutation-Related Tumors", "HER-2 Protein Overexpression", "HER2-negative Breast Cancer", "Triple Negative Breast Cancer", "HR Positive", "Hormone Receptor-positive Breast Cancer", "Estrogen Receptor Positive Tumor", "Progesterone Receptor-positive Breast Cancer", "Hormone Receptor Negative Breast Carcinoma", "Solid Tumor", "Solid Tumor, Adult", "Solid Carcinoma", "HER2 Low Breast Cancer", "HER2 Low Breast Carcinoma", "ER Positive Breast Cancer", "PR-positive Breast Cancer", "Minimal Residual Disease", "Colo-rectal Cancer", "Colon Cancer", "Rectal Cancer", "ctDNA Monitoring", "Colorectal Neoplasms", "Colonic Neoplasms", "Rectal Neoplasms", "Neoplasm, Residual", "Adenocarcinoma of Colon", "Adenocarcinoma" ], "interventions": [ { "name": "ALX148", "type": "DRUG" }, { "name": "Fam-Trastuzumab Deruxtecan-Nxki", "type": "DRUG" }, { "name": "Zanidatamab", "type": "DRUG" }, { "name": "Tucatinib", "type": "DRUG" }, { "name": "TTX-MC138", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "QuantumLeap Healthcare Collaborative", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 280, "start_date": "2023-02-15", "completion_date": "2031-12-30", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-09-08T22:32:04.486Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05868226" }, { "nct_id": "NCT06305715", "title": "Radiation Prior to TKI to Delay Progression in Advanced Driver-Mutated Non-small Cell Lung Cancers (RadiaNCe Lung X)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "Radiation Therapy", "type": "DEVICE" }, { "name": "Targeted TKI therapy", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2024-09-18", "completion_date": "2028-06-15", "has_results": false, "last_update_posted_date": "2025-10-07", "last_synced_at": "2026-09-08T22:32:04.486Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT06305715" }, { "nct_id": "NCT07638007", "title": "Impact of Targeted Therapy on Cancer-Related Cognitive Impairment", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Disease/Condition Name Cancer-related Cognitive Dysfunction", "Chronic Lymphocytic Leukemia (CLL)", "Chronic Myeloid Leukemia, BCR-ABL1 Positive" ], "interventions": [], "intervention_types": [], "sponsor": "University of Rochester NCORP Research Base", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 400, "start_date": "2025-11-21", "completion_date": "2029-02-28", "has_results": false, "last_update_posted_date": "2026-06-10", "last_synced_at": "2026-09-08T22:32:04.486Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07638007" }, { "nct_id": "NCT05256290", "title": "Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer", "Advanced Non-Small Cell Squamous Lung Cancer", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Lung Cancer", "NSCLC", "Advanced Lung Carcinoma", "Epidermal Growth Factor Receptor C797S", "Epidermal Growth Factor Receptor G719X", "EGF-R Positive Non-Small Cell Lung Cancer", "EGFR-TKI Resistant Mutation" ], "interventions": [ { "name": "silevertinib (BDTX-1535) monotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Black Diamond Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2022-03-31", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-09-08T22:32:04.486Z", "location_count": 25, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Huntington Beach, California + 20 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05256290" }, { "nct_id": "NCT01397734", "title": "Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Myelogenous Leukemia" ], "interventions": [ { "name": "Arsenic trioxide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Beth Israel Deaconess Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2011-09", "completion_date": "2018-08-06", "has_results": false, "last_update_posted_date": "2018-09-06", "last_synced_at": "2026-09-08T22:32:04.486Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01397734" }, { "nct_id": "NCT03958565", "title": "Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations.", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Tyrosine Kinase Inhibitor", "type": "BIOLOGICAL" }, { "name": "Zoledronic Acid 4 MG/100 ML Intravenous Solution [ZOMETA]", "type": "DRUG" }, { "name": "Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 100, "start_date": "2020-04-28", "completion_date": "2028-04-28", "has_results": false, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-09-08T22:32:04.486Z", "location_count": 2, "location_summary": "Aurora, Colorado • Lone Tree, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Lone Tree", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03958565" }, { "nct_id": "NCT02476955", "title": "Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors", "Ovarian Cancer", "Endometrial Cancer" ], "interventions": [ { "name": "ARQ 092 + carboplatin + paclitaxel (Closed)", "type": "DRUG" }, { "name": "ARQ 092 + paclitaxel (Closed)", "type": "DRUG" }, { "name": "ARQ 092 + anastrozole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 41, "start_date": "2015-06-09", "completion_date": "2019-05-07", "has_results": false, "last_update_posted_date": "2020-09-30", "last_synced_at": "2026-09-08T22:32:04.486Z", "location_count": 5, "location_summary": "Grand Rapids, Michigan • New York, New York • Oklahoma City, Oklahoma + 2 more", "locations": [ { "city": "Grand Rapids", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02476955" }, { "nct_id": "NCT03170960", "title": "Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Urothelial Carcinoma", "Renal Cell Carcinoma", "Non-Small Cell Lung Cancer", "Castration-resistant Prostate Cancer", "Triple Negative Breast Cancer", "Ovarian Cancer", "Endometrial Cancer", "Hepatocellular Carcinoma", "Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma", "Colorectal Cancer", "Head and Neck Cancer", "Differentiated Thyroid Cancer", "Lower Esophageal Cancer" ], "interventions": [ { "name": "cabozantinib", "type": "DRUG" }, { "name": "atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 914, "start_date": "2017-09-05", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2025-08-17", "last_synced_at": "2026-09-08T22:32:04.486Z", "location_count": 57, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 45 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03170960" } ] }